186593-14-6

Basic information

• Product Name: 5-(TRIFLUOROMETHYL)PYRIDIN-3-OL
• Synonyms: 5-(TRIFLUOROMETHYL)PYRIDIN-3-OL
• CAS NO: 186593-14-6
• Molecular Formula: C₆H₄F₃NO
• Molecular Weight: 163.1
• Mol File: 186593-14-6.mol

Chemical Properties

• Boiling Point: 301.2±37.0 °C(Predicted)
• Appearance: /
• Density: 1.423±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.28±0.10(Predicted)
• CAS DataBase Reference: 5-(TRIFLUOROMETHYL)PYRIDIN-3-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(TRIFLUOROMETHYL)PYRIDIN-3-OL(186593-14-6)
• EPA Substance Registry System: 5-(TRIFLUOROMETHYL)PYRIDIN-3-OL(186593-14-6)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 186593-14-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-(TRIFLUOROMETHYL)PYRIDIN-3-OL is used as a key intermediate in the synthesis of tricyclic dihydroimidazopyrimidone derivatives. These derivatives possess significant biological activity and are particularly effective as lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors.
As Lp-PLA2 inhibitors, these tricyclic dihydroimidazopyrimidone derivatives have the potential to modulate inflammatory processes and cardiovascular events by targeting the enzyme Lp-PLA2, which plays a crucial role in the production of pro-inflammatory mediators. This application highlights the importance of 5-(TRIFLUOROMETHYL)PYRIDIN-3-OL in the development of novel therapeutic agents for the treatment of various inflammatory and cardiovascular disorders.

Upstream product

• 85148-26-1 3-chloro-5-(trifluoromethyl)pyridine 

Downstream Products

• 1270497-74-9 cis-5-(trifluoromethyl)piperidin-3-ol 
• 1620579-56-7 3-fluoro-4-((5-(trifluoromethyl)pyridin-3-yl)oxy)benzaldehyde 
• 1421434-98-1 (3-fluoro-4-((5-(trifluoromethyl)pyridin-3-yl)oxy)phenyl)methanol 
• 1369255-53-7 5-(hydroxymethyl)-2-((5-(trifluoromethyl)pyridin-3-yl)oxy)benzonitrile 

Relevant articles and documents

DUAL MAGL AND FAAH INHIBITORS

Provided herein are compounds and pharmaceutical compositions comprising said compounds useful as modulators of MAGL and/or FAAH. The subject compounds and compositions are useful for the treatment of pain and neurological disorders.

2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2

The present invention relates to novel pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

INHIBITORS OF JAK

The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R′, X, X′, Y, Z1, Z2, and Z3 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release

Novel heterocyclic ether compounds of the formula: STR1 wherein n, *, R1, R2, R3 and y are specifically defined, or pharmaceutically acceptable salts or prodrugs thereof, which are useful in selectively controlling neurotransmitter release; therapeutically-effective pharmaceutical compositions of these compounds; and use of said compositions to selectively control neurotransmitter release in mammals.